Both ENVISION and ATLAS Phase 3 trials of UGN-102 met primary endpoints in treating low-grade intermediate-risk non‐muscle‐invasive bladder cancer (LG-IR-NMIBC). Reported record JELMYTO® net product revenues in Q2 2023 of $21.1 million , an increase of ~27% from the same period last year
-- Phase 3 ATLAS Clinical Trial Shows UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 -- PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 8, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to
Conference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Aug. 2, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 31, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) and options
PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 27, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN) (UroGen), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a definitive securities purchase
-- In ATLAS, UGN-102 Demonstrated Superiority to TURBT with a 55% Reduction of Risk for Recurrence, Progression or Death in Patients who Received UGN-102 -- -- ENVISION Showed a Complete Response Rate of 79.2% at 3-Months -- -- Side Effect Profile in ATLAS and ENVISION Consistent with Previous
PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 25, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of James Robinson , former President and Chief Executive
PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 10, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial
-- Program to Highlight Topline Results from the Phase 3 ATLAS and Pivotal ENVISION Clinical Trials -- PRINCETON, N.J. --(BUSINESS WIRE)--Jul. 6, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 20, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first post-commercial
